Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases by Bartsch, Rupert, Berghoff, Anna Sophie, Furtner, Julia, Marhold, Maximilian, Bergen, Elisabeth Sophie, Roider-Schur, Sophie, Mair, Maximilian Johannes, Starzer, Angelika Martina, Forstner, Heidrun, Rottenmanner, Beate, Aretin, Marie-Bernadette, Dieckmann, Karin, Bago-Horvath, Zsuzsanna, Haslacher, Helmuth, Widhalm, Georg, Ilhan-Mutlu, Aysegül, Minichsdorfer, Christoph, Fuereder, Thorsten, Szekeres, Thomas, Oehler, Leopold, Gruenberger, Birgit, Pfeiler, Georg, Singer, Christian, Weltermann, Ansgar, Berchtold, Luzia, Preusser, Matthias

Get full text